GO
Loading...

Actavis Inc

More

  • Mylan nears major deal for Abbott drugs: Sources Friday, 11 Jul 2014 | 6:42 PM ET

    U.S. generic drugmaker Mylan is said to be in advanced talks to buy a multibillion-dollar portfolio of established products from Abbott Laboratories.

  • Medical technology group Medtronic Inc said last month that it plans to buy Covidien Plc, a rival based in low-tax Ireland. The research service said other inversions have been done in the past decade by Mallinckrodt Pharmaceuticals, Perrigo Co Plc, Actavis Plc and other companies, many of them rebasing for tax purposes to Ireland.

  • Destination Maternity: Mothercare nixes proposals Wednesday, 2 Jul 2014 | 6:54 AM ET

    PHILADELPHIA— Destination Maternity says the U.K.' s Mothercare has rejected two proposals to combine the businesses. Destination Maternity said that Mothercare has refused to discuss the proposals and that it continues to evaluate its options on a potential combination.

  • Actavis closes $28B Forest deal, names new CEO Tuesday, 1 Jul 2014 | 10:22 AM ET

    Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company is now the CEO of Actavis. The Ireland- based drugmaker said Tuesday that Brenton L. Saunders will serve as Actavis president and CEO.

  • WASHINGTON, June 30- Generic drugmaker Actavis Plc has won U.S. approval to buy specialty pharmaceuticals company Forest Laboratories on condition it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.

  • Acorda's multiple sclerosis drug faces generic threat Thursday, 26 Jun 2014 | 6:36 AM ET

    June 26- Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda's multiple sclerosis treatment, Ampyra. Ampyra, which was approved in January 2010, had net sales of $72.5 million in the first quarter ended March 31.

  • *Move bolsters Shire in defence against AbbVie. *AbbVie to put its case to Shire shareholders- source. LONDON, June 25- Shire, which has spurned a $46 billion takeover offer from U.S. group AbbVie as inadequate, has a new reason to argue it is worth more after a U.S. court backed patent claims on its top-selling drug Vyvanse.

  • June 3- The city of Chicago has filed a lawsuit against five large narcotics makers alleging they contributed to the country's prescription drug epidemic by deceptively promoting their painkillers.

  • A bitter pill as China crackdowns squeeze pharma margins Saturday, 24 May 2014 | 10:00 PM ET

    China has been a magnet for the big global pharmaceutical companies and other healthcare firms as growth slows in Europe and the United States. While global drugmakers withhold their China profit figures, the analysis suggests profit growth is harder to come by- a concern as many global firms look to China as a future growth driver.

  • Eli Lilly loses UK Alimta patent case to Actavis Thursday, 15 May 2014 | 7:07 AM ET

    LONDON, May 15- Eli Lilly said on Thursday it had lost a patent case in the English High Court over its blockbuster Alimta lung cancer drug to generic drugmaker Actavis.

  • *Vivus has 7 U.S. patents for Qsymia, earliest expires in June 2020. May 9- Vivus Inc said on Friday drugmaker Actavis Plc plans to market a generic version of Vivus's obesity drug Qsymia that was approved in July 2012.

  • Vivus's diet pill faces generic threat from Actavis Friday, 9 May 2014 | 7:21 AM ET

    May 9- Vivus Inc said on Friday drugmaker Actavis Plc plans to market a generic version of Vivus's obesity drug Qsymia that was approved in July 2012. Actavis had filed a U.S. marketing application for its generic version of the diet pill, according to a notice sent by the generic drugmaker on May 7, Vivus said.

  • FACTBOX-M&A frenzy transforming global pharma Tuesday, 6 May 2014 | 2:00 PM ET

    MAY May 6- Merck& Co Inc agrees to sell its consumer care business to Germany's Bayer AG for $14.2 billion. May 2- Pfizer Inc raises its offer for AstraZeneca Plc to 63 billion pounds, but the British company promptly rejects the proposal, which would create the world's biggest pharmaceuticals company.

  • NEW YORK, May 1- Rumors about a massive healthcare deal were circulating in industry circles, months before Pfizer Inc disclosed its $100 billion pursuit of Britain's AstraZeneca Plc, according to several industry bankers and lawyers.

  • FACTBOX-M&A frenzy in healthcare sector Tuesday, 29 Apr 2014 | 2:25 PM ET

    **U.S. drugmaker Pfizer said on April 28 that it had offered to buy Britain's AstraZeneca Plc in January for about $98.9 billion, or nearly 47 pounds per share.

  • April 28- Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. A similar lawsuit was announced Friday by Mylan Inc over generic drug marketing exclusivity for Celebrex.

  • Actavis sues FDA over generic Celebrex Monday, 28 Apr 2014 | 5:51 PM ET

    April 28- Actavis Plc on Monday said it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.

  • *To pay $95/ share in cash, $30/ share in milestone payment. April 28- Forest Laboratories Inc said it would buy Furiex Pharmaceuticals Inc for up to $1.46 billion, including milestone payments, to add a promising treatment for irritable bowel syndrome to its gastrointestinal drugs portfolio.

  • STOCKHOLM, April 28- Swedish drugmaker Meda rejected an improved takeover offer from U.S. generics firm Mylan which one person familiar with the matter said valued Meda at around $9 billion including debt, driving its shares sharply back down.

  • Early movers: CMCSA, PFE, AZN, GE & more Monday, 28 Apr 2014 | 8:02 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.